Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

NY-ESO-1 is a “cancer-testis” antigen expressed in many cancers. ISCOMATRIX is a saponin-based adjuvant that induces antibody and T cell responses. We performed a placebo-controlled clinical trial evaluating the safety and immunogenicity of recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant. Fort...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Davis, Ian D., Chen, Weisan, Jackson, Heather, Parente, Phillip, Shackleton, Mark, Hopkins, Wendie, Chen, Qiyuan, Dimopoulos, Nektaria, Luke, Tina, Murphy, Roger, Scott, Andrew M., Maraskovsky, Eugene, McArthur, Grant, MacGregor, Duncan, Sturrock, Sue, Tai, Tsin Yee, Green, Simon, Cuthbertson, Andrew, Maher, Darryl, Miloradovic, Lena, Mitchell, Susan V., Ritter, Gerd, Jungbluth, Achim A., Chen, Yao-Tseng, Gnjatic, Sacha, Hoffman, Eric W., Old, Lloyd J., Cebon, Jonathan S.
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2004
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC489997/
https://ncbi.nlm.nih.gov/pubmed/15252201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0403572101
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars